Partnership with Industry
Strategic partnerships with global organisations help Scotland maintain its status as a global centre of research excellence
Working closely with industry is a key priority for NHS Research Scotland.
The NRS Industry Partnership Forum, formed in 2010, ensures close liaison between the NHS and the pharmaceutical industry. It is co-chaired by Chief Scientist Office (CSO) and Association of British Pharmaceutical Industry (ABPI) and provides a forum for positive discussion on how NHS Boards and companies can streamline their delivery of clinical studies.
NRS also has strategic collaborations with four industry partners:
- Announced on 9 February 2012, the Strategic Alliance with PPD is intended to cover a broad range of Phase I – III trials across multiple therapeutic areas
- NRS becoming a Quintiles Prime Site was announced at the inaugural NRS conference in October 2012, designed to increase the number of contract clinical trials conducted in Scotland
- On 31 October 2013, the Minister for Public Health announced that NHS Research Scotland has been awarded Pfizer global INSPIRE status, making Scotland a location of choice for Pfizer studies
- Most recently in May 2014, NRS entered into a Strategic Alliance with Roche, through which an increased number of contract and investigator initiated studies would be placed in Scotland
NRS Commercial Group
The aim of the NRS Commercial Group is to create a fast, predictable, supportive and enabling environment for industry to ensure that Scotland is the ‘go to’ place for commercial clinical research. The group will work to ensure a standard operational process which is central to our pan-Scotland ethos, as set out in the Scottish Governments 2015 Health and Social Care Research Strategy.
The group includes representation from commercial R&D teams across Scotland, NRS Operations group and is chaired by the NRS Industry Liaison Manager.